Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perioperative fractionated high-dose rate brachytherapy for malignant bone and soft tissue tumors.

International journal of radiation oncology, biology, physics·1999
Same author

[Endothelium-dependent relaxation of collateral microvessels following intramuscular gene transfer of vascular endothelial growth factor in a rat model of hindlimb ischemia].

Journal of cardiology·1999
Same author

[Hepatitis E].

Ryoikibetsu shokogun shirizu·1999
Same author

A pilot study of low-dose erythromycin in bronchiectasis.

The European respiratory journal·1999
Same author

Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes.

Journal of clinical pharmacy and therapeutics·1999
Same author

In vivo and in vitro trimethadione oxidation activity of the liver from various animal species including mouse, hamster, rat, rabbit, dog, monkey and human.

Human & experimental toxicology·1999

Related Experiment Video

Updated: Jul 14, 2026

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria
09:57

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Published on: December 14, 2016

[The need for new antituberculosis agents in Japan].

K Suzuki1, E Tanaka, R Amitani

  • 1Department of Infectious Disease, Kyoto University Hospital, Japan.

Kekkaku : [Tuberculosis]
|March 6, 1999
PubMed
Summary

New antituberculosis agents are needed in Japan due to frequent adverse reactions and drug interactions with current standard chemotherapy. Many patients experienced side effects, necessitating treatment changes and highlighting the need for safer alternatives.

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Related Experiment Videos

Last Updated: Jul 14, 2026

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria
09:57

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Published on: December 14, 2016

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Clinical Medicine

Background:

  • Standard antituberculosis chemotherapy in Japan involves isoniazid (INH), rifampicin (RFP), ethambutol (EB), streptomycin (SM), and pyrazinamide (PZA).
  • Drug adverse reactions, interactions, and resistance pose significant challenges in tuberculosis treatment.
  • There is a critical need for novel antituberculosis agents with improved safety profiles.

Purpose of the Study:

  • To evaluate the incidence and types of adverse reactions associated with standard antituberculosis chemotherapy in hospitalized patients in Japan.
  • To assess the impact of these adverse reactions on treatment completion.
  • To highlight the necessity for developing new antituberculosis drugs with reduced toxicity and fewer drug interactions.

Main Methods:

  • Retrospective review of medical charts of 228 hospitalized patients undergoing standard antituberculosis chemotherapy.
  • Analysis of symptoms, signs, and laboratory data to identify chemotherapy-induced adverse reactions.
  • Categorization of adverse reactions by drug and severity, and assessment of treatment modifications.

Main Results:

  • Approximately 48% of patients experienced at least one adverse reaction.
  • Hepatotoxicity (77 episodes), ototoxicity (15), eruption (14), and ocular toxicity (14) were common.
  • Adverse reactions led to treatment discontinuation in 59 cases and incomplete standard chemotherapy in 23% of patients.
  • Rifampicin (RFP) was associated with adverse reactions in 23% of treated cases, streptomycin (SM) in 20%, isoniazid (INH) in 12%, and ethambutol (EB) in 7.7%.

Conclusions:

  • Current standard antituberculosis chemotherapy in Japan is associated with a high incidence of adverse reactions, impacting treatment completion.
  • Rifampicin's significant drug interaction potential, particularly via CYP3A4 induction, limits its co-administration with other vital medications.
  • Development of new antituberculosis agents with enhanced efficacy, reduced adverse reactions, and minimal drug-drug interactions is urgently required in Japan.